Scheinberg D A
Sloan-Kettering Institute, New York, New York.
Curr Opin Immunol. 1991 Oct;3(5):679-84. doi: 10.1016/0952-7915(91)90096-j.
Recent trials of monoclonal antibodies in patients with leukemias or lymphomas have demonstrated the remarkable potency of these agents to kill tumor cells specifically and safely. New molecular biological and radiochemical techniques are also allowing rapid inroads into the remaining obstacles to this mode of therapy.